Connect with us

National

Chamisa’s CCC set for landslide victory in parly, council by-elections

Published

on

BY GIBBS DUBE

Zimbabwe’s Citizens Coalition for Change (CCC)  led by Nelson Chamisa, which was set up two months ago, is heading for a landslide victory in council and parliamentary by-elections held on Saturday.

Advertisement

Official results announced by the Zimbabwe Electoral Commission (ZEC) indicate that CCC has retained almost all parliamentary seats in urban areas.

CCC has conceded defeat in Mutasa South where its candidate got 5,269 votes compared to the ruling party’s candidate who amassed 5,818 votes.

In tweet, CCC said, We lost this seat to Zanupf.”

Advertisement

CCC leader, Nelson Chamisa, said in a tweet, “This by-election has shown that ultimately all authority comes from the citizens.

“Citizens are above politicians & their foolish politics.

“Why did you waste national resources tax payers money? Would these resources not have been deployed to better our health, education sectors?”

Advertisement

Zanu PF says the party will issue a statement after analysing all the results.

There were 28 parliamentary and 122 council seats that were up for grabs nationwide.

BY-ELECTION RESULTS (Preliminary)

Advertisement

Constituency: Mufakose Province: Harare CCC: 4039 Zanupf: 1128 MDC Alliance : 218 Winner: CCC Susan Matsunga

Constituency: Glenview North Province: Harare CCC: 4053 Zanupf: 1578 MDC Alliance : 112 NPF: 20 Winner: CCC Fani Munengami

Constituency: Mutasa South Province: Manicaland CCC: 5269 Zanupf: 5818 MDC Alliance : 162 Independent: 50 Winner: We lost this seat to Zanupf

Advertisement

Constituency: Kambuzuma Province: Harare CCC: 3092 Zanupf: 1333 MDC Alliance : 108 Winner: CCC Willias Madzimure

Constituency: Glen-Norah Province: Harare CCC: 5098 Zanupf: 1552 MDC Alliance : 280 UDA :18 RPZ: 49 Winner: CCC Wellington Chikombo

Constituency: Nkulumane Province: Bulawayo CCC: 2760 Zanupf: 1900 MDC Alliance : 150 DOP:18 RPZ: 45 Winner: CCC Phulu Kucaca

Advertisement

Constituency: Marondera Central Province: Mashonaland East CCC: 6756 Zanupf: 4200 MDC Alliance:292 Independent:55 Winner: CCC Caston Matewu

Constituency: St Mary’s Province: Harare CCC: 5830 Zanupf: 4483 MDC Alliance:201 Independent : 55 Winner: CCC Tarusenga Unganayi Dickson

Constituency: Harare East Province: Harare CCC: 7534 Zanupf: 3045 MDC Alliance:114 UZA: 100 LEAD: 25 Winner: CCC Laxton Tendai Biti

Advertisement

Constituency:Dangamvura-Chikanga Province: Manicaland CCC: 13132 Zanupf: 6304 MDC Alliance:341 PZ: 209 MA/AT 57 Winner: CCC Mutseyami Chapfiwa Prosper

Constituency: Pumula Province: Bulawayo CCC: 3092 Zanupf: 1212 MDC Alliance:110 ZAPU:227 UDA: 33 RPZ: 27 Independent: 62 Winner: CCC Mahlangu Sichelesile

Advertisement

National

Tragic attack in Madlambuzi: Five dead as suspected mental patient goes on rampage

Published

on

BY WANDILE TSHUMA 

Police in Madlambuzi, Matabeleland South Province has are a suspected mental patient, Phamani Sibanda, following a violent rampage that left five people dead and two others injured on Wednesday.

Advertisement

According to the police statement, Sibanda (43) allegedly attacked seven people in the village using a Mopani log, a blunt object, and an unknown sharp weapon, targeting anyone who crossed his path.

The victims of this tragic attack have been identified by their next of kin:

Elliot Khupe, 101, a male adult from Bellas Village
Butho Tshuma, 97, a female adult from Bellas Village
Constance Sibanda, 66, a female adult from Bellas Village
Tiffan Surprise Ndlovu, 6, a female juvenile from Bellas Village
Catra Matsika, 72, from Central Village

Advertisement

In addition to the fatalities, two other women, aged 90 and 41, sustained injuries and are currently receiving treatment at Madlambuzi Clinic and Plumtree District Hospital.

The ZRP has underscored the pressing need for community awareness regarding mental health issues. “We implore the public to promptly refer mental patients to medical institutions for treatment and to actively monitor their behavior to prevent such violent incidents,” the statement elaborated. It encouraged community members to report any concerns to the National Complaints Desk at (0242) 703631 or via WhatsApp at 0712 800197, or to approach the nearest police station.

 

Advertisement

Continue Reading

National

US suspends visa processing in Zimbabwe, embassy says

Published

on

BY REUTERS

The United States has stopped processing most visas in Zimbabwe until further notice, its embassy in the capital Harare said on Wednesday, citing unspecified concerns with the government.
“We have paused routine visa services in Harare while we address concerns with the Government of Zimbabwe,” the embassy said in a post on X. It said the move was not a travel ban and that current visas would remain valid.
The government of the Southern African country did not immediately reply to a request for comment.
The pause took effect on August 7, according to a notice on the U.S. State Department’s website, which said it applied to all visa services with the exception of most diplomatic and official visas.
U.S. President Donald Trump’s administration has restricted travel from a number of African countries, saying it is working to prevent visa overstaying and misuse.
Zimbabwe had a visa overstay rate of 10.57% in 2023, according to a U.S. Department of Homeland Security report.
Starting this week, the U.S. will require visa applicants from Zambia and Malawi to pay bonds of up to $15,000 for some visitor visas. The Trump administration has also paused visa processing in Niger.
Harare resident Angella Chirombo said her 18-year-old son had received a scholarship to do his bachelor’s degree at Michigan State University and had been waiting for a visa interview when the pause hit.
“He was supposed to be in school already. I paid for everything else and was waiting for the visa so I could buy tickets,” she told Reuters.
She said other parents were considering booking interviews at other U.S. embassies in Southern Africa, but that she wouldn’t be able to afford the travel.
“Now they are saying we can go to Zambia and Namibia. I don’t even have money right now and I don’t know where to get this money. They are so many students that have been affected.”

Continue Reading

National

Landmark HIV trial begins in Zimbabwe

Published

on

BY PAUL SIXPENCE

ZIMBABWE became the first site for the administration of a new investigational HIV vaccine. The first doses of the IAVI C114 clinical trial were administered in late July 2025 at the Mutala Trust clinical site in Harare, CITE reports.

Advertisement

“This is a landmark moment for South Africa, Zimbabwe, and the continent. It shows the power of true partnership,” said Dr. Tariro Makadzange, clinical trial lead, Mutala Trust.

“We are edging closer to an HIV vaccine, made possible by global collaboration, with clinical trials conducted in Africa, for Africa, and for the world.”

The development of the vaccine is a partnership that brings together Zimbabwe’s Mutala Trust, ReiThera, the Ragon Institute, International AIDS Vaccine Initiative (IAVI) and African researchers who are co-leading every phase of the trial.

Advertisement

In phase one of the trial, the vaccine candidate, Gorilla Adenovirus Vectored HIV Networked Epitopes Vaccine (GRAdHIVNE1) will be administered to 120 adults between the ages of 18 and 50 years including 48 people living with HIV who are virally suppressed on antiretroviral therapy (ART). Besides Zimbabwe, two other clinical trial sites are located in Cape Town and Durban, South Africa.

Trial sites were chosen on the basis of their high HIV burden and to ensure that the vaccine candidate is tested within communities affected by the epidemic.

This phase of the trial will assess the safety and ability of the vaccine candidate to provoke an immune response in the human body in persons living with HIV and those who are HIV negative.

Advertisement

“The IAVI C114 trial is testing a new vaccine candidate known as GRAdHIVNE1. The trial represents the first time this vaccine is being tested in humans and is aimed at assessing the safety of the vaccine and its ability to stimulate the immune system,” said Dr. Vincent Muturi-Kioi, HIV Vaccines Product Development Team Lead, IAVI.

In a statement, IAVI further advised that “trial participants will receive either one or two doses of the investigational vaccine or a placebo and will be monitored over a period of 19 months for safety and immune responses.” Results of the trial are likely to be available in 2027.

In the past, several HIV vaccine trials have been conducted but none proved effective in preventing HIV acquisition. The novelity of this vaccine candidate lies in that, it uses a harmless viral vector to deliver small parts of HIV “derived from critical structural regions of HIV that are less likely to mutate” with an expected likelihood to trigger an immune response.

Advertisement

“GRAdHIVNE1 uses a harmless virus (a vector for the vaccine derived from a non-replicating gorilla adenovirus) to deliver small, conserved parts of HIV (called epitopes) to the body’s immune system. These targets are derived from critical structural regions of HIV that are less likely to mutate, making them good targets for killer T cells in the immune system (CD8+ T cell responses) — a type of immune defense thought to be important for long-term protection against HIV. The viral vector was selected based on its ability to stimulate this type of response. Should the vaccine be successful in stimulating the desired response, it could be tested in future trials to assess its efficacy,” Dr. Vincent Muturi-Kioi further explained.

The initiation of this clinical trial demonstrates the power of partnerships at a time when the world is witnessing funding cuts towards global public health research. The IAVIC114 clinical trial is sponsored by IAVI. The vaccine candidate, GRAdHIVNE1, was developed by ReiThera and the Ragon Institute with funding from the GatesFoundation. African researchers will be leading

SOURCE| CITE

Advertisement

Continue Reading

Trending

Copyright © 2022 VicFallsLive. All rights reserved, powered by Advantage